Skip to main content
43°
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
News
Local News
State News
Sports
Local Sports
Pro Sports
Lifestyle
Local Entertainment
Multimedia
Community Choice
Features
Special Sections
Local Events
Weather
Classifieds
Place Ad
Legal Notices
Place Call Legal
Search Call Legals
Place Times Legal
Search Times Legals
Public Notices
Obituaries
E-Edition
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Arcus Biosciences, Inc. Common Stock
(NY:
RCUS
)
9.540
-0.160 (-1.65%)
Official Closing Price
Updated: 7:00 PM EDT, Mar 13, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Arcus Biosciences, Inc. Common Stock
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
Arcus Biosciences Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update
February 23, 2022
From
Arcus Biosciences, Inc.
Via
Business Wire
Arcus Biosciences's Earnings: A Preview
February 22, 2022
Arcus Biosciences (NYSE:RCUS) is set to give its latest quarterly earnings report on Wednesday, 2022-02-23. Here's what investors need to know before the announcement. Analysts...
Via
Benzinga
"Prudent" Biotech Bets
February 20, 2022
Here, we review two recommended biotechnology stocks following the release of their latest earnings reports. Let's take a look.
Via
Talk Markets
Arcus Biosciences to Participate in the Upcoming Investor Conferences
February 15, 2022
From
Arcus Biosciences
Via
Business Wire
Arcus Biosciences Announces New Employment Inducement Grants
February 09, 2022
From
Arcus Biosciences
Via
Business Wire
Earnings Scheduled For February 23, 2022
February 23, 2022
Companies Reporting Before The Bell • Sapiens Intl Corp (NASDAQ:SPNS) is likely to report earnings for its fourth quarter. • Plymouth Industrial REIT (NYSE:PLYM)...
Via
Benzinga
Gilead Stock Dives After Two Major Charges Dig Into Fourth-Quarter Earnings
February 01, 2022
Gilead shares toppled after hours on lighter-than-expected fourth-quarter profit.
Via
Investor's Business Daily
Arcus Biosciences Announces New Employment Inducement Grants
January 25, 2022
From
Arcus Biosciences
Via
Business Wire
Arcus Biosciences Announces New Employment Inducement Grants
January 11, 2022
From
Arcus Biosciences, Inc.
Via
Business Wire
Arcus Biosciences Provides Update on Clinical Programs, Including Key 2022 Milestones
January 10, 2022
From
Arcus Biosciences, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Tuesday's After-Market Session
January 04, 2022
Gainers Oncternal Therapeutics (NASDAQ:ONCT
Via
Benzinga
Arcus Biosciences Announces New Employment Inducement Grants
December 24, 2021
From
Arcus Biosciences
Via
Business Wire
Gilead and Arcus Biosciences Complete Closing of Option Exercise for Three Clinical-Stage Programs and New Research Collaboration
December 21, 2021
From
Arcus Biosciences, Inc.
Via
Business Wire
Arcus Biosciences Announces New Employment Inducement Grants
December 09, 2021
From
Arcus Biosciences, Inc.
Via
Business Wire
Why Arcus Biosciences Stock Vaulted Higher in November
December 09, 2021
Arcus was one of the few winners in the turbulent biotech space last month.
Via
The Motley Fool
Taiho Pharmaceutical Exercises Option for an Exclusive License to Arcus Biosciences’ Anti-TIGIT Program in Japan and Certain Territories in Asia
November 30, 2021
From
Arcus Biosciences, Inc.
Via
Business Wire
Arcus Biosciences to Participate in the Upcoming Evercore ISI HealthCONx 2021 Conference
November 22, 2021
From
Arcus Biosciences, Inc.
Via
Business Wire
54 Biggest Movers From Yesterday
November 19, 2021
Gainers Longeveron Inc. (NASDAQ: LGVN) shares climbed 135.3% to close at $6.87 on Thursday. Longeveron said the FDA granted rare pediatric disease designation for the company...
Via
Benzinga
Exposures
Product Safety
Arcus Stock Rockets To Record As Gilead Unexpectedly Opts Into Cancer Drugs
November 18, 2021
Gilead opted into three programs from a small biotech company, sending shares flying.
Via
Investor's Business Daily
12 Health Care Stocks Moving In Thursday's Intraday Session
November 18, 2021
Gainers Dicerna Pharmaceuticals (NASDAQ:DRNA) shares moved upwards by 78.87% to $38.06 during Thursday's regular session. As of 12:30 EST, this security is trading at...
Via
Benzinga
44 Stocks Moving In Thursday's Mid-Day Session
November 18, 2021
Gainers Longeveron Inc. (NASDAQ: LGVN) jumped 157% to $7.51. Longeveron said the FDA granted rare pediatric disease designation for the company’s Lomecel-B for the...
Via
Benzinga
Exposures
Product Safety
Why Are Arcus Biosciences Shares Trading Higher Today?
November 18, 2021
Gilead Sciences Inc (NASDAQ: GILD) has exercised its options to three programs in Arcus Biosciences Inc (NYSE: RCUS) portfolio, including both anti-TIGIT...
Via
Benzinga
Why Arcus Biosciences Stock Is On Fire Today
November 18, 2021
Gilead Sciences has decided to exercise its options for three of the biotech's oncology programs.
Via
The Motley Fool
12 Health Care Stocks Moving In Thursday's Pre-Market Session
November 18, 2021
Gainers Dicerna Pharmaceuticals (NASDAQ:DRNA) stock increased by 78.28% to $37.94 during Thursday's pre-market session. The market value of their outstanding shares is...
Via
Benzinga
Gilead Exercises Options to Three Arcus Biosciences Clinical-Stage Programs and Adds Research Collaboration
November 18, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
Arcus Biosciences Announces New Employment Inducement Grants
November 09, 2021
From
Arcus Biosciences, Inc.
Via
Business Wire
Recap: Arcus Biosciences Q3 Earnings
November 08, 2021
Arcus Biosciences (NYSE:RCUS) reported its Q3 earnings results on Monday, November 8, 2021 at 04:10 PM. Here's what investors need to know about the announcement. Earnings...
Via
Benzinga
Arcus Biosciences Reports Third Quarter 2021 Financial Results and Provides an Update on our anti-TIGIT Domvanalimab
November 08, 2021
From
Arcus Biosciences, Inc.
Via
Business Wire
Arcus Biosciences to Report Third Quarter 2021 Financial Results & Recent Corporate Highlights
November 02, 2021
From
Arcus Biosciences, Inc.
Via
Business Wire
Earnings Scheduled For November 8, 2021
November 08, 2021
Companies Reporting Before The Bell • Privia Health Group (NASDAQ:PRVA) is projected to report quarterly loss at $0.11 per share on revenue of $215.14 million. •...
Via
Benzinga
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.